Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha
therapy is an active area of academic and commercial research worldwide. Objectives …

The 18‐membered macrocycle H2macropa was investigated for 225Ac chelation in targeted
alpha therapy (TAT). Radiolabeling studies showed that macropa, at submicromolar …

Lanmodulin (LanM) is a recently discovered protein that undergoes a large conformational
change in response to rare-earth elements (REEs). Here, we use multiple physicochemical …

The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly
promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle …

Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …

Actinium is an elusive element with untamed properties and represents a peculiar case in
the periodic table, as its isotopes are all radioactive, the longest-lived one having only a 22 …

Understanding the bonding, reactivity and electronic structure of actinides is lagging behind
that of the rest of the periodic table. This can be partly explained by the challenges that one …

The hydroxypyridinone ligand 3, 4, 3-LI (1, 2-HOPO) is a promising agent for biological
decorporation of radionuclides, and allows spectroscopic detection of many lanthanide (Ln) …

While uranyl-based metal–organic frameworks (MOFs) boast impressive photocatalytic
abilities, significant questions remain regarding their excitation pathways and methods to …